Immuneering Corporation (IMRX)
Immuneering Statistics
Share Statistics
Immuneering has 35.99M shares outstanding. The number of shares has increased by 21.02% in one year.
| Shares Outstanding | 35.99M |
| Shares Change (YoY) | 21.02% |
| Shares Change (QoQ) | 15.58% |
| Owned by Institutions (%) | 14.42% |
| Shares Floating | 22.4M |
| Failed to Deliver (FTD) Shares | 402 |
| FTD / Avg. Volume | 0.19% |
Short Selling Information
The latest short interest is 1.07M, so 2.97% of the outstanding shares have been sold short.
| Short Interest | 1.07M |
| Short % of Shares Out | 2.97% |
| Short % of Float | 3.77% |
| Short Ratio (days to cover) | 5.98 |
Valuation Ratios
The PE ratio is 0 and the forward PE ratio is -0.66. Immuneering's PEG ratio is 0.
| PE Ratio | 0 |
| Forward PE | -0.66 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0 |
| P/FCF Ratio | -1.2 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Immuneering.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.28, with a Debt / Equity ratio of 0.1.
| Current Ratio | 5.28 |
| Quick Ratio | 5.28 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -75.57 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-924.8M |
| Employee Count | 66 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 2.8% in the last 52 weeks. The beta is -0.26, so Immuneering's price volatility has been lower than the market average.
| Beta | -0.26 |
| 52-Week Price Change | 2.8% |
| 50-Day Moving Average | 1.55 |
| 200-Day Moving Average | 1.76 |
| Relative Strength Index (RSI) | 51.45 |
| Average Volume (20 Days) | 214.9K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -64.07B |
| Net Income | -61.04B |
| EBITDA | -64.07B |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2035.8 |
Balance Sheet
The company has 36.14B in cash and 4.16B in debt, giving a net cash position of 31.98B.
| Cash & Cash Equivalents | 36.14B |
| Total Debt | 4.16B |
| Net Cash | 31.98B |
| Retained Earnings | -224.3B |
| Total Assets | 52.71M |
| Working Capital | 32.08M |
Cash Flow
In the last 12 months, operating cash flow was -55M and capital expenditures -84.88K, giving a free cash flow of -55.08M.
| Operating Cash Flow | -55M |
| Capital Expenditures | -84.88K |
| Free Cash Flow | -55.08M |
| FCF Per Share | -1.84 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IMRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IMRX is $12.5, which is 750.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.5 |
| Price Target Difference | 750.3% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Scores
| Altman Z-Score | -6.62 |
| Piotroski F-Score | 2 |